SciSparc’s SCI-110 Study: A Potential Game-Changer for Tourette Syndrome
SciSparc Ltd. ((SPRC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. is advancing its clinical study titled A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome. The study aims to assess the effectiveness and safety of SCI-110, a cannabinoid-based medication, in managing Tourette Syndrome symptoms.
The intervention under investigation is SCI-110, an experimental drug composed of Dronabinol and Palmitoylethanolamide (PEA). It is designed to alleviate symptoms of Tourette Syndrome through its cannabinoid properties.
The study follows a randomized, double-blind, placebo-controlled, cross-over design. Participants, care providers, investigators, and outcomes assessors are all blinded to the treatment assignments. The primary goal is to evaluate the treatment’s efficacy.
Key dates for the study include its initial submission on October 25, 2021, and the latest update on May 13, 2025. The study is currently not yet recruiting, indicating that participant enrollment has not started.
This update could influence SciSparc’s stock performance as investors anticipate the potential success of SCI-110 in the market. The study’s progress may also impact investor sentiment positively, given the increasing interest in cannabinoid-based treatments. Competitors in the pharmaceutical industry may closely monitor these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.
